Articles

Resurrect Bio, a biotechnology company revolutionizing agriculture by equipping crops with genetic defenses against disease, today announced the successful initial closing of its Series A funding round at $8.1M. The investment was led by Corteva Agriscience through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S, SynBioVen, and AgFunder.

The completion of this Series A round represents a significant milestone for Resurrect Bio, reflecting growing industry recognition of the urgent need for sustainable crop protection solutions. The funds will enable Resurrect Bio to accelerate its high-throughput trait discovery platform and advance multiple disease resistance products toward commercial partnerships, bringing solutions to farmers significantly faster than conventional breeding methods.

Resurrect Bio’s proprietary platform combines cutting-edge FloraFold® AI computational biology and high-throughput screening in plants to identify and resurrect disease resistance genes that have been suppressed by pathogens. The resurrection process involves making small changes to the native plant genes using gene editing, restoring the crop’s ability to defend itself against pathogens. This approach is poised to offer farmers a novel pathway to protect yields against the plant diseases that threaten global food security.

"We're thrilled to have secured this investment from such a distinguished group of partners who share our vision of delivering durable disease resistance to farmers," said Dr. Cian Duggan, CEO of Resurrect Bio. "With Corteva's leadership and the support of Calculus Capital, Pymwymic and our existing investors, we're now positioned to scale our platform and deliver multiple resistance traits to the seed industry."

Corteva, through its Corteva Catalyst platform, collaborates with entrepreneurs and innovators to accelerate the development of early-stage, disruptive technologies that enable farmers to sustainably produce more food and feed.